FLAMAZINE Cream 1 % w/w (Silver sulfadiazine 1% w/w)
Abbreviated Prescribing Information
Please refer to Summary of Product Characteristics (SmPC) before prescribing

**Presentations:** Tube containing 50g and jars containing 250g or 500g silver sulfadiazine 1% w/w.

**Indications:** Prophylaxis and treatment of infection in burn wounds, leg ulcers and pressure sores due to micro-organisms sensitive to this anti-infective. Conservative management of finger-tip injuries where pulp, nail loss and/or partial loss of the distal phalanx has occurred.

**Dosage and Administration:** To be applied topically. **Burns and Leg Ulcers/Pressure Sores:** Apply a layer approx. 3-5mm thick to the affected area using a sterile glove or spatula. Then cover area with an absorbent gauze dressing and support bandage where necessary. Dressing should be changed and FLAMAZINE cream applied at least every 24 hours in burn treatment, or at least three times weekly otherwise, and debridement carried out as necessary.

**Finger-Tip Injuries:** Achieve haemostasis of injury prior to application of a 3-5mm layer of FLAMAZINE cream. A conventional finger dressing may be used. Change dressings every 2-3 days.

**Contraindications, Precautions and Warnings:** Do not use in lactating women who are breast-feeding infants, on premature infants or newborn infants during the first three months of life, or in patients known to be hypersensitive to sulfonamides, silver sulfadiazine or other components of the cream. Care should be taken to avoid spread onto non-ulcerated areas. Prolonged use of an anti-infective may result in the development of superinfection. Fungal colonisation may occur. Use with extreme caution in patients with respiratory impairment or hepatic or renal function impairment and in individuals known to have glucose-6-phosphate deficiency. Use of FLAMAZINE cream may delay separation of burn eschar and may alter the appearance of burn wounds. One container should be reserved for use in a single patient and the remaining contents discarded after treatment is completed.

**Interactions:** Silver may inactivate enzymatic debriding agents. With use in large-area burns, effects of oral hypoglycaemic agents and phenytoin may be potentiated.

**Pregnancy and lactation:** Only use during pregnancy or lactation if considered essential by the physician.

**Undesirable Effects:** Application site rash, pruritus, leucopenia, renal failure, argyria. Consult SmPC for further information about adverse events.

**Legal Category:** POM

**Product Authorisation No.:** PA 710/3/1

**Marketing Authorisation Holder:** Smith & Nephew Pharmaceuticals Ltd., 101 Hessle Road, Hull, HU3 2BN, England

Further information is available on request from the Marketing Authorisation Holder

**Date of Preparation:** August 2011

Adverse events should be reported to:
Smith & Nephew Healthcare Ltd.,
101 Hessle Road, Hull HU3 2BN, UK
Tel: +44 1482 222200